Skip to main content

Aldeyra Therapeutics, Inc.

corporate_fare Company Profile

Aldeyra Therapeutics, Inc.

ALDX·NASDAQ·Life Sciences·CIK 0001341235

Aldeyra Therapeutics is a biotechnology company focused on discovering innovative therapies for immune-mediated diseases. The company develops pharmaceuticals that modulate protein systems to optimize multiple pathways simultaneously while minimizing toxicity, rather than directly inhibiting or activating single protein targets. Its product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and related molecules for potential treatment of systemic and retinal immune-mediated diseases. Late-stage product candidates include reproxalap, a RASP modulator for potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. On October 31, 2023, Aldeyra Therapeutics entered into an exclusive option agreement with AbbVie Inc. This agreement granted AbbVie an exclusive option to obtain a co-exclusive license in the United States for collaboration on reproxalap development, manufacturing, and commercialization, and an exclusive license for reproxalap development, manufacturing, and commercialization outside the United States. AbbVie also received a right of first negotiation for Aldeyra's ophthalmology compounds related to ocular surface conditions and a right to review data for other ophthalmology and immunology compounds before sharing with third parties. Aldeyra Therapeutics received a non-refundable payment of $1.0 million for this option. On December 21, 2023, AbbVie extended the option period with an additional non-refundable payment of $5.0 million.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for ALDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ALDX spans 8-K, 10-Q, 4, 10-K.

Recent high-impact activity:

  • Aldeyra Gets Nasdaq Bid-Price Notice, Has Until May 17, 2027 to Reclaim $1.00
  • Aldeyra Seeks FDA Division Transfer for ADX-2191, Withdraws Agreed SPA Protocol
  • Aldeyra Q3: Cash Down to $41M, Loss Narrows, FDA Appeal Pending
  • Aldeyra to Appeal FDA Rejection of Reproxalap via Formal Dispute Resolution Request
  • Aldeyra Charts a Path to reproxalap NDA Resubmission Following FDA Type A Meeting

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$33.85M
Diluted EPS
-$0.56
Op. Cash Flow
-$33.35M
Operating Income
-$35.27M
Cash & Equivalents
$70.04M
Total Debt
$15.25M
Debt / Equity
0.34×
Shares Outstanding
60.16M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-083012

Short Interest & Short Volume

3.44 days to cover

FINRA reported short interest of 3,159,816 shares in ALDX as of the October 30, 2026 settlement, a 0.8% decrease from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 53.2% of ALDX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,159,816 shares as of October 30, 2026
Change vs prior period▼ 0.8%
Days to cover3.44 at avg daily volume of 917,902
Daily short volume (FINRA facilities)53.2% of 1,767,551 shares on November 20, 2026
5-day average short volume49.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.81 -3.57% today
52-week range · as of 2026-11-17 $0.5271 – $5.93
Market cap
$50.7M
Volume
2.5M (2.6× avg)
3-mo avg 978.8K
Live data · 2026-11-21 10:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALDX - Latest Insights

ALDX
Nov 17, 2026, 4:50 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6939
Real-time Price: $0.810 info
Change: +$0.1161 (+17%) info
Market Cap: $50.699M info
ALDX
Nov 09, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.636
Real-time Price: $0.810 info
Change: +$0.174 (+27%) info
Market Cap: $50.699M info
ALDX
Nov 05, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6159
Real-time Price: $0.810 info
Change: +$0.1941 (+32%) info
Market Cap: $50.699M info
ALDX
Sep 29, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.810 info
Change: -$0.3888 (-32%) info
Market Cap: $50.699M info
ALDX
Jul 15, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.810 info
Change: -$1.11 (-58%) info
Market Cap: $50.699M info
ALDX
Jun 09, 2026, 8:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $0.810 info
Change: -$0.910 (-53%) info
Market Cap: $50.699M info
ALDX
Jun 05, 2026, 4:19 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.810 info
Change: -$0.9897 (-55%) info
Market Cap: $50.699M info
ALDX
May 18, 2026, 9:08 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.810 info
Change: -$0.790 (-49%) info
Market Cap: $50.699M info
ALDX
May 07, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.75
Real-time Price: $0.810 info
Change: -$0.940 (-54%) info
Market Cap: $50.699M info
ALDX
Apr 01, 2026, 5:17 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $0.810 info
Change: -$0.910 (-53%) info
Market Cap: $50.699M info
ALDX
Apr 01, 2026, 4:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $0.810 info
Change: -$0.910 (-53%) info
Market Cap: $50.699M info
ALDX
Mar 17, 2026, 8:39 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $0.810 info
Change: -$0.560 (-41%) info
Market Cap: $50.699M info
ALDX
Feb 27, 2026, 4:47 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $0.810 info
Change: -$4.51 (-85%) info
Market Cap: $50.699M info
ALDX
Jan 02, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.42
Real-time Price: $0.810 info
Change: -$4.61 (-85%) info
Market Cap: $50.699M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets